Rivermark Medical, a Milwaukee, WI-based company which specializes in minimally invasive solutions for Benign Prostatic Hyperplasia (BPH), raised $30M in Series C funding.
The round was led by American Century Investments (ACI) including new investors Venture Investors Health Fund, Time BioVentures, and an unnamed strategic investor, with follow-on participation from existing investors View Ventures, Cadence Healthcare Ventures, and Anduril Investors LLC.
The company intends to use the funds to advance the clinical development of its flagship product, the FloStent™ System, designed to restore urinary function for BPH patients.
Led by Adam Kadlec, President and CEO, Rivermark Medical was founded to develop a first-line device therapy for benign prostatic hyperplasia. The FloStent System enables physicians to treat patients safely and efficiently, with minimal discomfort and reduced complications. It is designed to rapidly restore normal urinary function, preserve sexual function, and improve a patient’s overall quality of life.
The device is currently in clinical development.
FinsMEs
10/10/2024